Day One Biopharmaceuticals Stock (NASDAQ:DAWN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$16.39

52W Range

$10.90 - $18.07

50D Avg

$14.34

200D Avg

$14.65

Market Cap

$1.60B

Avg Vol (3M)

$1.02M

Beta

-1.52

Div Yield

-

DAWN Company Profile


Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

174

IPO Date

May 27, 2021

Website

DAWN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 24Jun 24
License$73.69M-
Product$20.07M$8.19M

Fiscal year ends in Dec 23 | Currency in USD

DAWN Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-206.06M$-146.91M$-72.74M
Net Income$-188.92M$-132.18M$-70.44M
EBITDA$-206.06M$-146.91M$-72.74M
Basic EPS-$-2.02$-1.91
Diluted EPS-$-2.02$-1.91

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 30, 24 | 10:57 PM

Peer Comparison


TickerCompany
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
PDSBPDS Biotechnology Corporation
HOOKHOOKIPA Pharma Inc.
TERNTerns Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
ELDNEledon Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.